Good news｜Hezheng Pharmaceutical and Neo-Ocean Pharmaceuticals have reached a licensing agreement-Hangzhou Hezheng Pharmaceutical Co., Ltd.

Recently, Hangzhou Hezheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Hezheng Pharmaceutical") and Neurosyntherapeutics (hereinafter referred to as "Niosyn") jointly announced that the two parties have reached a cooperation on a pipeline of projects for the treatment of central nervous system (CNS) diseases. According to the terms of the agreement, Nuosin will obtain the global exclusive development rights, registration and commercialization rights of the project. The indications include epilepsy, affective disorders, etc. Based on this cooperation, Hezheng Pharmaceutical will receive down payment, R&D milestone payments, etc. Dr. Zhou Xinglu, co-founder and CEO of Hezheng Pharmaceuticals, said: "We are honored and pleased to reach a cooperation with Neurosyn. Hesheng Pharmaceuticals has always been committed to the research and development of new therapeutic drugs driven by cutting-edge technology. The project of this cooperation is another case based on the output of Hesheng Pharmaceuticals' small molecule drug development platform. We believe that Neosyn, with its rich research and development experience in the field of CNS treatment, will quickly advance this project into the clinical development stage and bring positive therapeutic effects to patients as soon as possible." "We are pleased to enter into this collaboration with Hezheng Pharmaceuticals," said Dr. Shen Huaqiong, founder and CEO of Nuosin Pharmaceuticals. "We will continue to carry out a full range of preclinical research and pharmaceutical development, and formulate and execute our clinical development strategies based on compound characteristics and clinical needs of target indications. This project will further strengthen our pipeline layout in the field of psychiatric and psychological diseases." As the global demographic structure changes and aging intensifies, CNS diseases have become a major health and social problem faced by various countries. There are a large number of patients with CNS diseases, and they often have chronic disease characteristics, causing great pain and harm to patients. This project is a Class I innovative drug project independently developed by Hezheng Pharmaceutical. The molecule has shown unique advantages and good efficacy in various CNS models in vivo and in vitro, and is expected to become a new potential treatment drug for epilepsy, affective disorders and other diseases. About Neosyn Pharmaceuticals is a biotechnology company focusing on the development of innovative drugs for the central nervous system. It has an innovation-driven engine for AAV-based gene therapy and small molecule drug therapy. New Ocean was founded by a world-class professional team and has a scientific committee composed of accomplished industry leaders. The company has R&D centers in Shanghai, China and Boston, USA.